Fig. 8
From: Development of a computational promoter with highly efficient expression in tumors
Inhibitory effect of D5 mini-promoter-driven expression of the therapeutic gene RBDV IgG1 Fc on tumor growth. a C57BL/6 mice (5 animals per group) were subcutaneously implanted with 1 × 106 B16F10 tumor cells/mouse. When the average tumor sizes reached 50 mm3, the mice were in situ injected with PBS, or LPPC/pCMV-RDBV-IgG1 Fc, LPPC/ pCMV-IgG1 Fc, pD5-RDBV-IgG1 Fc or LPPC/pD5-IgG1 Fc complexes. Tumor growth was monitored every 2 days, and tumor sizes were calculated as described in the Methods section. For the pD5-RBDV-IgG1 Fc group, * indicates p < 0.05 compared with the PBS group and # indicates p < 0.05 compared with the pCMV-RBDV-IgG1 Fc group. b B16F10 tumors were collected and photographed after the mice were sacrificed at 21 days